Loading company…
Polyphron develops AI-guided tissue engineering technology for disease treatment, drug development and regenerative medicine.
Polyphron develops AI-guided tissue engineering technology to manufacture and simulate human tissues. It combines stem cell biology, automated laboratory systems and machine learning to create functional replacement tissues. The technology targets disease treatment, drug development and regenerative medicine. The company was founded in 2024 and is based in New York, US.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in